Business Context and Reporting Period
Company: DAXOR CORP
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: September 30, 1998
Business Overview: Daxor operates clinical laboratories, including a semen bank and blood bank in New York State, and is developing a Blood Volume Analyzer. The company's operations have been significantly impacted by long-standing legal proceedings with the New York State Department of Health regarding its laboratory licenses.
Key Financial Metrics
| Metric | Nine Months Ended Sep 30, 1998 | Nine Months Ended Sep 30, 1997 |
|---|---|---|
| Total Revenues | $2,088,320 | $2,624,810 |
| Operating Revenues | $259,303 | $420,897 |
| Dividend Income | $1,475,648 | $1,611,393 |
| Net Income (Loss) | $(181,018) | $761,263 |
| Net Cash from Operating Activities | $(623,952) | $398,175 |
| Total Assets | $43,179,990 | $41,322,592 |
| Total Liabilities | $8,054,790 | $8,404,868 |
| Shareholders' Equity | $35,125,200 | $32,917,724 |
| Loans Payable | $1,659,481 | $2,494,639 |
| Cash and Cash Equivalents | $89,686 | $60,768 |
Note: The company holds marketable securities with a fair value of $42,184,210, representing a significant portion of total assets. Net unrealized holding gains on these securities are $12,302,210 (after tax).
Material Changes vs. Prior Period
- Revenue Decline: Total revenues decreased by approximately 20% year-over-year. Operating revenues dropped significantly from $420,897 to $259,303 due to restrictions on laboratory and blood banking operations.
- Profitability Shift: The company moved from a net income of $761,263 in the prior year to a net loss of $181,018. This was driven by lower operating revenues and increased net interest expense ($447,464 in 1998 vs. $114,375 in 1997).
- Cash Flow: Operating cash flow turned negative, using $623,952, compared to a positive $398,175 in the prior period. This was largely due to the net loss and adjustments for gains on the sale of investments.
- Debt Reduction: Loans payable decreased by approximately $835,000, primarily due to the repayment of short-term margin debt to brokers.
Outlook, Risks, and Management Commentary
- Legal Resolution: On November 3, 1998, Daxor signed an agreement with the New York State Department of Health to end litigation. This involves creating a separate subsidiary, Scientific Medical Systems, to operate the semen and blood banks. Management anticipates this will restore revenue from these sources.
- New Product Focus: The company is shifting focus to the marketing of the Blood Volume Analyzer. It has acquired assets from Wellport, Inc., and holds Letters of Intent from ten major teaching hospitals to test the device. No revenue has been generated from this product yet.
- Liquidity: Management states the company has adequate liquid capital to sustain current operations and market the new analyzer. However, a nationwide expansion of blood banking would require additional capital.
- Risks: Continued reliance on investment income and unrealized gains; potential delays in the re-opening of banking facilities; and the success of the new Blood Volume Analyzer in generating revenue.
- Y2K Compliance: A contract has been initiated for a new computer system to be installed within 90 days to address Year 2000 issues.
Investor Verification Checklist
- Verify the operational status and revenue generation timeline of the new subsidiary, Scientific Medical Systems, following the November 1998 agreement.
- Confirm the progress of the Blood Volume Analyzer trials with the ten teaching hospitals and the timeline for commercial sales.
- Assess the sustainability of the company's reliance on dividend income and unrealized gains on marketable securities versus core operating revenue.
- Review the terms of the $1.66 million in outstanding loans and the collateral requirements (marketable securities).
- Monitor the company's cash burn rate given the negative operating cash flow for the nine-month period.